Wave Life Sciences Aligns With FDA on Single Registrational Trial for WVE-006 in AATD
Wave plans a single two-year trial for WVE-006 in AATD after FDA feedback, with a one-year review for possible accelerated approval.
/ 9 items
#WVE↓
WVE-007 Shows Muscle-Preserving Fat Loss in Early Data, But Weight Reduction Remains Modest
Wave Life Sciences' WVE-007 (INHBE-targeted) showed ~5% total fat reduction and 14% visceral fat drop with muscle preserved after one dose. Early results are modest (1% weight loss), but support infrequent dosing as potential GLP-1 complement.
BofA Gives Wave Life Sciences a Buy Rating, Eyes $38 Target
Bank of America starts coverage of Wave Life Sciences (WVE) with a Buy rating. Analyst highlights WVE-007 in obesity as a major growth driver, with peak sales above $11B.
Arrowhead Gene Drug Doubles Weight Loss in Obesity Trial
Arrowhead Pharmaceuticals' (ARWR) ARO-INHBE gene-silencing drug combined with Zepbound doubles weight loss in obese diabetes patients, targeting dangerous visceral and liver fat more effectively.
HHS Adds Rare Diseases to Newborn Tests, Sarepta Rises
Sarepta rises as HHS recommends newborn screening for Duchenne muscular dystrophy and metachromatic leukodystrophy, aiming for earlier diagnosis and treatment.
Wave Life Sciences' Obesity Drug Shows Promising Fat Loss Without Muscle Decline
Wave Life Sciences' WVE-007 demonstrates 9.4% visceral fat reduction with muscle preservation in Phase 1 trial, earning positive analyst ratings and buy recommendations.